News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MT Newswires Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
[Partnership word near puzzle pieces. Teamwork concept. Strategic cooperation. Reliable partner. 3d render] Independent biopharmaceutical company Specialised Therapeutics announced an expansion of its partnership [https://seekingalpha.com/pr/20657284-specialised-therapeutics-expands-partnership-with-incyte-to-include-ruxolitinib-cream] with Incyte Biosciences International, an affiliate of Incyte Corporation (INCY [https://seekingalpha.com/symbol/INCY]), to register, commercialize, and distribute ruxolitinib cream (marketed …
Specialised Therapeutics has expanded its partnership with Incyte Biosciences International to commercialize ruxolitinib cream (Opzelura) in Australia. This cream is a topical Janus kinase inhibitor used for conditions like non-segmental vitiligo and atopic dermatitis. Specialised Therapeutics will handle regulatory submissions, marketing, and distribution in …
SINGAPORE, Sept. 20, 2026 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) today announced an expansion of its existing partnership with Incyte Biosciences International, an affiliate of Incyte (NASDAQ: INCY), to commercialise, distribute, and register ruxolitinib cream (registered as Opzelura® in the U.S. and …
This Benzinga article provides a comprehensive overview of Incyte Corp (INCY) stock, including its current price, key statistics, recent news, financial data, and analyst trends. It details the company's focus on small-molecule drugs, its leading product Jakafi, and its market performance. The article also …
This article examines Incyte Corporation (NASDAQ:INCY) through the lens of its commercial portfolio and clinical pipeline progress, emphasizing that durable demand and disciplined execution are more critical than short-term market sentiment. It discusses how the company's business fundamentals interact with broader market conditions, including …
Incyte (NASDAQ:INCY) is identified as a strong investment candidate by combining Mark Minervini's Trend Template with high-growth momentum criteria. The stock exhibits robust technical strength, including being in a Stage 2 uptrend with high relative strength, and strong fundamental growth with accelerating earnings and …
Incyte (INCY) drew fresh attention after Ontario agreed to fund MINJUVI for relapsed or refractory follicular lymphoma through its FAST Program, giving eligible patients earlier access while reimbursement reviews continue. For context, Incyte's share price has climbed 27.0% over the past 90 days and …
Cantor Fitzgerald has reiterated a Neutral rating on Incyte (NASDAQ: INCY) shares, noting the strong market appeal and off-label use of its topical treatment Opzelura for hidradenitis suppurativa. Despite this, the firm maintains its rating following discussions with Incyte executives. The article also highlights …
Shares of Incyte INCY have rallied 23% year to date compared with the industry's growth of 5.2%. The stock has also outperformed the medical sector and the S&P 500 Index during this time frame. Much of this rally came after the company reported strong …
Incyte (INCY): 3 Reasons We Love This Stock Incyte's 29% return over the past six months has outpaced the S&P 500 by 15.7%, and its stock price has climbed to $119.95 per share. This was partly thanks to its solid quarterly results, and the …
Incyte (NASDAQ: INCY) has significantly outperformed the market over the last 20 years, achieving an average annual return of 17.44%. An initial investment of $1,000 in Incyte 20 years ago would now be worth $25,320.17, highlighting the substantial impact of compounded returns. The company …
Cantor Fitzgerald has maintained a Neutral rating on Incyte (NASDAQ: INCY) following an investor breakfast at their Global Healthcare Conference. Incyte's management reinforced its strategy to achieve $3 billion to $4 billion in durable core business revenue by 2030, excluding Jakafi, and to advance …
Incyte stock is trading just below a buy zone just as Big Money is giving it the stamp of approval. Shares popped in July following a strong earnings report that impressed investors. Incyte stock shows an ideal Composite Rating of 99, boosted by steady …
Incyte Corporation discussed its pipeline advancements and post-Jakafi strategy at the 12th Annual Cantor Fitzgerald Global Healthcare Conference. The company is focusing on growing its core business to $3-4 billion with multiple launches and developing five cornerstone assets in Phase III trials to support …
Incyte announced that MINJUVI® (tafasitamab) for relapsed or refractory follicular lymphoma (R/R FL) has been funded in Ontario through the FAST Program, making Ontario the first province to provide public access to this treatment for FL. This accelerated funding pathway allows eligible patients to …
Incyte Corp. (INCY) shares rose by 1.29% to $126.01 on Wednesday, outperforming the broader market as the S&P 500 Index and Dow Jones Industrial Average both experienced declines. This increase ended a three-day losing streak for the stock.
Incyte (INCY) plans to drive significant revenue growth post-2029 through a dual strategy focusing on core business expansion and pipeline execution. The company is developing five late-stage assets in hematology, oncology, and immunology. This strategy includes franchise-building in GI oncology and hematology, innovative clinical …
Incyte Corporation (INCY) presented its long-term growth strategy at the Wells Fargo 21st Annual Healthcare Conference, aiming to diversify beyond its flagship drug Jakafi. The company projects its core business (excluding Jakafi) to achieve double-digit growth through 2030, reaching $3 billion to $4 billion …
Shares of Incyte Corp. slid 1.85% on Tuesday, marking its third consecutive day of losses. Despite the decline, the stock outperformed the broader market, which saw the S&P 500 Index fall 0.58% and the Dow Jones Industrial Average fall 1.18%.
Incyte Corporation (INCY) is drawing investor attention due to its substantial 37.70% revenue growth and promising therapeutic pipeline within the biotechnology sector. With a market cap of $25.69 billion and a stock price near its 52-week high, the company demonstrates strong financial health, evidenced …
Incyte (Nasdaq: INCY) announced it will present at three investor conferences in September: the 21st Annual Wells Fargo Healthcare Conference on September 9th, the Cantor Global Healthcare Conference 2026 on September 10th, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 16th. …
Search by ticker symbol or company name and select a result to open its chart.
Start typing to find a stock or ETF.
Choose one or more countries for market search, or include every covered market.
Currently searching United States